Albany, NY -- (SBWIRE) -- 03/13/2019 -- Chronic lymphocytic leukemia (CLL) is a form of cancer that originates from lymphocytes in the bone marrow and later invades the blood and/or lymphoid tissues. CLL treatment has been transformed since the novel oral targeted agents Imbruvica (ibrutinib), Zydelig (idelalisib), and Venclexta (venetoclax) were introduced to the market from 2014 onwards and challenged the prior dominance of chemoimmunotherapy regimens.
Get Free PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=2170080
During the forecast period, the global CLL market will welcome five new drugs-Calquence (acalabrutinib), zanubrutinib, umbralisib, ublituximab, and Revlimid (lenalidomide).
The CLL marketed is expected to experience modest growth in the 7MM (US, France, Germany, Italy, Spain, UK and Canada) from 2017-2027. This is driven by increasing incidence, driven primarily by aging populations, label expansions into the first-line setting for AbbVie/Roches Venclexta, frontline approval of the combination of AbbVie/Johnson & Johnsons Imbruvica + Venclexta, and the increasing use of combination therapies instead of monotherapies or chemoimmunotherapy regimens. Generic and biosimilar erosion of some of the mainstays of CLL treatment is also expected during the forecast period, particularly the use of generic ibrutinib and biosimilar rituximab will lead to a decline in sales. A lack of innovative drugs in the late-stage pipeline with novel mechanisms of action means that next-generation agents are not expected to generate significant sales.
Key Questions Answered
- Which pipeline agents are the most promising and expected to launch in the 7MM? What are the forecasted sales of these agents and what will be their impact in the CLL market?
- What are the main unmet needs in CLL, which pipeline drugs will fulfil these needs, and to what extent?
- What are the current research and development (R&D) strategies being explored and how can developers incorporate these methods into their business strategy?
Scope
- Overview of CLL, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized CLL therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven geographic regions, forecast from 2017 to 2027.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the CLL therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for CLL. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the global CLL market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=2170080
Companies mentioned
AbbVie
Acerta Pharma
ADC Therapeutics
Adlai Nortye Biopharma
Aptevo Therapeutics
ArQule
Asana BioSciences
Astellas
AstraZeneca
Bayer
BeiGene
Biogen Idec
BioInvent International
Boehringer Ingelheim
Boston Biomedical
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/